SavedAdd your journal

Journals / İzmir Dr. Behçet Uz Çocuk Hastanesi Dergisi / 2014 / Cilt: 4 - Sayı: 3

Comparing azithromycin (1.5%) with netilmicin (0.3%) eye drops in pediatric population with bacterial conjunctivitis

Çocuklardaki bakteriyel konjonktivit tedavisinde azitromisin (%1,5) ile netilmisin (%0.3) göz damlasının karşılaştırılması

Mehmet Özgür ZENGİN
Neslihan ZENGİN
Esat ÇINAR
Cem KÜÇKERDÖNMEZ
Pages
182–185
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Despite their similar clinical responses in the treatment of children with bacterial conjunctivitis, azithromycin (1.5%) eye drops is safe and can be administered with a more convenient twice-a-day dosing regimen.when compared with netilmicin (0.3%) eye drops.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To compare the safety and efficacy of 1.5% azithromycin eye drops with 0.3% netilmicin ophthalmic solution in a pediatric population with purulent bacterial conjunctivitis.
📊
Key Findings & Data:Methods: Patients received either azithromycin (1.5%) (Group 1) (twice daily for 3 days) or netilmicin (0.3%) (Group 2) eye drops (four times daily for 7 days) to treat bacterial conjunctivitis.
💡
Conclusion & Impact:Conclusion: Despite their similar clinical responses in the treatment of children with bacterial conjunctivitis, azithromycin (1.5%) eye drops is safe and can be administered with a more convenient twice-a-day dosing regimen.when compared with netilmicin (0.3%) eye drops.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To compare the safety and efficacy of 1.5% azithromycin eye drops with 0.3% netilmicin ophthalmic solution in a pediatric population with purulent bacterial conjunctivitis. Methods: Patients received either azithromycin (1.5%) (Group 1) (twice daily for 3 days) or netilmicin (0.3%) (Group 2) eye drops (four times daily for 7 days) to treat bacterial conjunctivitis. Clinical signs were evaluated on day 3 and 7. The primary variable was the clinical cure (absence of bulbar conjunctival injection and discharge) on day 3 for Group 1 and day 7 for Group 2. Results: A total of 92 patients were randomized, and both study medications were well tolerated. Clinical signs were evaluated on day 3 and 7. Clinical cure rate was similar between two groups (91.3% vs 89.3%, respectively). The most frequently observed ocular adverse events in the azithromycin group were eye irritation (15.2%) and con- junctival hyperemia (13.0%) in the netilmicin %0.3 group. Conclusion: Despite their similar clinical responses in the treatment of children with bacterial conjunctivitis, azithromycin (1.5%) eye drops is safe and can be administered with a more convenient twice-a-day dosing regimen.when compared with netilmicin (0.3%) eye drops.

Özet

Amaç: Bu çalışmada çocuklardaki bakteriyel konjonktivit tedavisinde azitromisin %1,5 göz damlası ile netilmisin %0.3 göz damlasının tedavideki etkinlik ve güvenirliliğinin karşılaştırılması amaçlanmıştır. Yöntemler: Hastalara bakteriyel konjonktivit tedavisi için azitromisin %1,5 (Grup 1) göz damlası (3 gün günde 2 kez) veya netilmisin %0,3 (Grup 2) göz damlası (günde 4 kez 1 hafta boyunca) uygulanmıştır. Klinik bulgular 3. ve 7. günde değerlendirilmiş - tir. Klinik iyileşme (konjonktival hiperemi ve sekresyonun olmaması) Grup 1’de 3. gün, Grup 2’de 7. gün değerlendirilmiştir. Bulgular: Toplam 92 olgu randomize edilmiş ve iki grupta da tedavi iyi tolere edilmiş tir. Klinik yanıt 3. ve 7. günde değerlendirilmiştir. Tedavi yanıtı iki grupta da birbirine yakın saptanmıştır. (sırasıyla, %91,3 ve %89,1). En sık rastlanan oküler yan etki azitromisin grubunda göz irritasyonu (%15,2) iken, netilmisin %0,3 grubunda kon- jonktival hiperemi (%13,0) olarak görülmüştür. Sonuç: Çocuklardaki bakteriyel konjonktivit tedavisinde, benzer klinik yanıtlar görülmüş olsa da, azitromisin %1,5 göz damlası netilmicin %0.3 göz damlasına göre daha kısa süreli ve günde iki kez uygulanması açısından daha uygun ve güvenilir gözükmektedir.

🔖

Cite This Article

ZENGİN, M. Ö., ZENGİN, N., ÇINAR, E., KÜÇKERDÖNMEZ, C. (2014). Comparing azithromycin (1.5%) with netilmicin (0.3%) eye drops in pediatric population with bacterial conjunctivitis. İzmir Dr. Behçet Uz Çocuk Hastanesi Dergisi, Cilt: 4 - Sayı: 3, 182–185. https://ajindex.com/articles/210431

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Patel PB, Diaz MC, Bennett JE, Attia MW. Clinical features of bacterial conjunctivitis in children. Acad Emerg Med 2007;14:1-5.
  2. Syed NA, Chandler JW. Bacterial conjunctivitis. In: Tabbara KF, Hyndiuk RA. Eds. Infections of the eye. Vol. 8. 2nd edn. Boston, USA. Little, Brown and Co., 1986: 69-84
  3. Martin M, Turco JH, Zegans ME, et al. An outbreak of con - junctivitis due to atypical Streptococcus pneumoniae. N Engl J Med 2003;348:1112-1121.
  4. Sheikh A, Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: a systematic review. Br J Gen Pract 2001;51:473-477
  5. Sheikh A, Hurwitz B, van Schayck CP, McLean S, Nurmatov U. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev 2012;9:CD001211
  6. Hwang DG, Schanzlin DJ, Rotberg MH, Foulks G, Raizman MB. A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacteri- al conjunctivitis. Br J Ophthalmol 2003;87:1004-1009.
  7. Sheikh A. Acute bacterial conjunctivitis. In: Wormald R, Smeeth L, Henshaw K, eds. Evidence-based ophthalmology. Vol
  8. London, UK: BMJ Books, 2004: 33-35
  9. Otkun MT, Özbey N, Kömür B, Çömez AT, Akçalı A, Eser İ. Bakteriyel Konjonktivit Tedavisinde Antibiyotik Tercihi ne Olmalı? Turkish J Ophthalmol 2010;40(6):354-358
  10. Papa V, Aragona P, Scuderi AC, Blanco AR, Zola P, Di BA, et al. Treatment of acute bacterial conjunctivitis with topical netilmicin. Cornea 2002;21(1):43-47.
  11. Lichtenstein SJ, Rinehart M. Efficacy and safety of 0.5% levofloxacin ophthalmic solution for the treatment of bacteri- al conjunctivitis in pediatric patients. J AAPOS 2003;7:317- 324.
  12. Rietveld RP, ter Riet G, Bindels PJ, Sloos JH, van Weert HC. Predicting bacterial cause in infectious conjunctivitis: cohort study on informativeness of combinations of signs and symptoms. BMJ 2004;329:206-210.
  13. Schwab IR, Friedlaender M, McCulley J, Lichtenstein SJ, Moran CT. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Ophthalmology 2003;110:457-465.
  14. Yee RW, Tepedino M, Bernstein P